Gland Pharma’s Earnings To Compound Led By Foray Into New Markets, Complex Injectables, Portfolio Expansion, Says Nirmal Bang
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
Gland Pharma Ltd. is one of the fastest-growing generic injectable-focused companies by revenue.
Shanghai Fosun Pharma Co. (Chinese MNC) is the promoter company of Gland Pharma and is a global pharmaceutical major.
A business-to-business model together with a sharp focus on manufacturing of sterile dosage forms (injectable and ophthalmic) allows the company to operate on a very lean cost structure and also ensures regulatory compliance on a consistent basis.
Ensuring consistent regulatory compliance is potentially a cornerstone of a successful injectable business, but unfortunately it has emerged as an Achilles heel for most generic companies.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.